Author

T. Moreno

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Agraz-Doblas· 1 shared A. Astudillo· 1 shared A. D. Tran· 1 shared A. Lius· 1 shared B. Casar· 1 shared B. Monterde· 1 shared C. Morales Torres· 1 shared C. Revilla· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Agraz-Doblas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Generation of anti-tumor chimeric antigen receptors incorporating T cell signaling motifs

L. Balagopalan, T. Moreno, H. Qin, J. Yi, K. M. M. McIntire, N. Alvinez, S. Pallikkuth, M. E. Lee, H. Yamane, A. D. Tran, P. Youkharibache, R. E. Cachau, N. Taylor, L. E. Samelson

This paper develops novel Chimeric Adapter Proteins (CAPs) that enhance T cell signaling and anti-tumor efficacy compared to conventional CAR-T cells.

bioRxiv · Dec 25, 2022 · PreprintImmunology

Multiplexed profiling of kinase interactomes quantifies cellular network plasticity

M. Golkowski, A. Lius, T. S. Sapre, H.-T. Lau, T. Moreno, D. J. Maly, S.-E. Ong

The paper introduces Ki-CCA, a method to map kinase PPIs across cancer cell lines, revealing network plasticity and identifying therapeutic targets.

bioRxiv · Sep 14, 2021 · PreprintBiochemistry

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer

T. Moreno, L. Gonzalez-Silva, B. Monterde, I. Betancor-Fernandez, C. Revilla, A. Agraz-Doblas, J. Freire, P. Isidro, L. Quevedo, S. Montes-Moreno, L. Cereceda, A. Astudillo, B. Casar, P. Crespo, C. Morales Torres, , I. Varela

This study identifies ARID2 deficiency in 20% of lung cancer patients, showing it promotes tumor progression and increases sensitivity to PARP inhibition.

bioRxiv · Jan 10, 2020Cancer Biology